100 related articles for article (PubMed ID: 26991431)
1. Joining forces: first application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in Leishmania.
Späth GF; Clos J
Mol Microbiol; 2016 Jun; 100(6):923-7. PubMed ID: 26991431
[TBL] [Abstract][Full Text] [Related]
2. Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation.
Duncan SM; Myburgh E; Philipon C; Brown E; Meissner M; Brewer J; Mottram JC
Mol Microbiol; 2016 Jun; 100(6):931-44. PubMed ID: 26991545
[TBL] [Abstract][Full Text] [Related]
3. DiCre-Based Inducible Disruption of Leishmania Genes.
Duncan SM; Myburgh E; Alves-Ferreira EV; Mottram JC
Methods Mol Biol; 2019; 1971():211-224. PubMed ID: 30980305
[TBL] [Abstract][Full Text] [Related]
4. DiCre-Based Inducible Gene Expression.
Damasceno JD; Tosi LRO; Santos RERS; Mottram JC
Methods Mol Biol; 2019; 1971():225-235. PubMed ID: 30980306
[TBL] [Abstract][Full Text] [Related]
5. Conditional transgenesis using Dimerizable Cre (DiCre).
Jullien N; Goddard I; Selmi-Ruby S; Fina JL; Cremer H; Herman JP
PLoS One; 2007 Dec; 2(12):e1355. PubMed ID: 18159238
[TBL] [Abstract][Full Text] [Related]
6. A DiCre recombinase-based system for inducible expression in Leishmania major.
Santos RERS; Silva GLA; Santos EV; Duncan SM; Mottram JC; Damasceno JD; Tosi LRO
Mol Biochem Parasitol; 2017 Sep; 216():45-48. PubMed ID: 28629935
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in Leishmania reverse genetics: Manipulating a manipulative parasite.
Duncan SM; Jones NG; Mottram JC
Mol Biochem Parasitol; 2017 Sep; 216():30-38. PubMed ID: 28629934
[TBL] [Abstract][Full Text] [Related]
8. Conditional Gene Deletion in Mammalian and Mosquito Stages of Plasmodium berghei Using Dimerizable Cre Recombinase.
Fernandes P; Loubens M; Silvie O; Briquet S
Methods Mol Biol; 2021; 2369():101-120. PubMed ID: 34313986
[TBL] [Abstract][Full Text] [Related]
9. Universal highly efficient conditional knockout system in Leishmania, with a focus on untranscribed region preservation.
Yagoubat A; Crobu L; Berry L; Kuk N; Lefebvre M; Sarrazin A; Bastien P; Sterkers Y
Cell Microbiol; 2020 May; 22(5):e13159. PubMed ID: 31909863
[TBL] [Abstract][Full Text] [Related]
10. 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.
Řezníčková E; Popa A; Gucký T; Zatloukal M; Havlíček L; Bazgier V; Berka K; Jorda R; Popa I; Nasereddin A; Jaffe CL; Kryštof V; Strnad M
Bioorg Med Chem Lett; 2015 Jun; 25(11):2298-301. PubMed ID: 25937014
[TBL] [Abstract][Full Text] [Related]
11. Genetically Validated Drug Targets in Leishmania: Current Knowledge and Future Prospects.
Jones NG; Catta-Preta CMC; Lima APCA; Mottram JC
ACS Infect Dis; 2018 Apr; 4(4):467-477. PubMed ID: 29384366
[TBL] [Abstract][Full Text] [Related]
12. Why strategies to control Leishmania spp. multiplication based on the use of proteinase inhibitors should consider multiple targets and not only a single enzyme.
Alves CR; Pereira BA; Silva-Almeida M; da Silva FS
J Mol Model; 2014 Oct; 20(10):2465. PubMed ID: 25296889
[TBL] [Abstract][Full Text] [Related]
13. Essential gene identification and drug target prioritization in Leishmania species.
Paul ML; Kaur A; Geete A; Sobhia ME
Mol Biosyst; 2014 May; 10(5):1184-95. PubMed ID: 24643243
[TBL] [Abstract][Full Text] [Related]
14. Leishmania mexicana: expression; characterization and activity assessment of E. coli-expressed recombinant CRK3.
Ali NO; Ibrahim ME; Grant KM; Mottram JC
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(10):1338-45. PubMed ID: 23104649
[TBL] [Abstract][Full Text] [Related]
15. A non-commercial approach for the generation of transgenic Leishmania tarentolae and its application in antileishmanial drug discovery.
Pineda T; Valencia Y; Flórez MF; Pulido SA; Vélez ID; Robledo SM
Parasitology; 2016 Aug; 143(9):1133-42. PubMed ID: 27174193
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance analysis by next generation sequencing in Leishmania.
Leprohon P; Fernandez-Prada C; Gazanion É; Monte-Neto R; Ouellette M
Int J Parasitol Drugs Drug Resist; 2015 Apr; 5(1):26-35. PubMed ID: 25941624
[TBL] [Abstract][Full Text] [Related]
17. Advances and perspectives in Leishmania cell based drug-screening procedures.
Sereno D; Cordeiro da Silva A; Mathieu-Daude F; Ouaissi A
Parasitol Int; 2007 Mar; 56(1):3-7. PubMed ID: 17079188
[TBL] [Abstract][Full Text] [Related]
18. Conditional removal of selectable markers in Trypanosoma cruzi using a site-specific recombination tool: proof of concept.
Kangussu-Marcolino MM; Cunha AP; Avila AR; Herman JP; DaRocha WD
Mol Biochem Parasitol; 2014 Dec; 198(2):71-4. PubMed ID: 25619800
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the leishmanicidal and cytotoxic effects of inhibitors for microorganism metabolic pathway enzymes.
de Mesquita Barbosa A; Dos Santos Costa S; da Rocha JR; Montanari CA; Giorgio S
Biomed Pharmacother; 2015 Aug; 74():95-100. PubMed ID: 26349969
[TBL] [Abstract][Full Text] [Related]
20. Genetics. Leishmania exploit sex.
Miles MA; Yeo M; Mauricio IL
Science; 2009 Apr; 324(5924):187-9. PubMed ID: 19359570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
